Re: Wikipedia on Investor Relations: Goal is Fair Valuation
in response to
by
posted on
May 25, 2016 03:51PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
One way to prove value is by putting the stock on a market like the NASDAQ. Potential investors will establish value.
However, with RVX and Zenith's very poor marketing, communications and strategy I actually don't want them to get the stock listed until zen3694 performs some sort of miracle on castration resistant metatstatic prostate cancer.
Don let us down in 2 ways. The first was that he failed on his promise of a Q4 Zenith IPO and the second is that he backed away from a NASDAQ listing.
Both of these failures have an impact on the perceived value of RVX indirectly IMHO.
But, it does looke like the science could be extremely powerful, again IMHO.
Toinv